Skip to content

Prediction of Preterm Delivery by Serum Ischemia Modified Albumin, Biglycan and Decorin Levels in Women With Threatened Preterm Labour

Prediction of Preterm Delivery by Serum Ischemia Modified Albumin, Biglycan and Decorin Levels in Women With Threatened Preterm Labour

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04451928
Enrollment
51
Registered
2020-06-30
Start date
2019-12-01
Completion date
2021-02-05
Last updated
2021-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth

Keywords

preterm birth, ischemia modified albumin, biglycan, decorin, prediction

Brief summary

In this study, the levels of ischemia modified albumin, biglycan and decorin in the serums of pregnant women hospitalized for preterm labor will be examined. Their serum levels will be compared between women having preterm and term delivery. Their accuracy will be asessed in predicting preterm birth.

Detailed description

The study will include 90 singleton pregnant women between the ages of 18 and 42 and gestational ages of 24 and 37 weeks. Inclusion criteria: * Singleton pregnancy * Gestational age between 24 and 37 weeks * Cervical dilatation less than 3 cm and cervical effacement less than 80% * Uterine contraction ≥3 times at 30 minutes * Intact amniotic membrane Excusion criteria: * Multiple pregnancy * Preterm premature rupture of membranes * Abnormal placentation (such as placenta previa) * Uterin anomaly * Maternal heart disease * Inflammatory or infectious disease * Preeclampsia * Fetal growth restriction * Congenital fetal anomaly * Polyhydramnios * Acute chorioamnionitis * Medically induced preterm delivery Patients who are hospitalized due to preterm labor will primarily receive bed rest and hydration. If cervical changes persist or if contractions continue after 2 hours after intravenous hydration, tocolytic treatment will be started. Calcium channel blockers will be used as tocolytic drug. Maternal corticosteroid (12 mg intramuscular betamethasone within 24 hours) will be given to accelerate fetal lung development. After 48 hours after steroid administration, tocolysis will be stopped. Demographic datas of the patients will be recorded. Patients will be followed until delivery. The gestational week will be determined according to the last menstrual date and will be confirmed by early ultrasonographic measurements. The gestational week at birth and the time between admission to the hospital and birth will be recorded. Delivery time will be divided into groups within 24 hours, 48 hours, 7 days, 14 days, and ≤37 weeks after admission. Mode of delivery, baby's birth weight, APGAR score will be recorded. Venous blood samples will be taken from patients before medication. Serum samples will be stored in the cooler set to -80 °C until analysis. Levels of ischemia-modified albumin, biglycan and decorin levels will be examined by enzyme-linked immunosorbent assay (ELISA) method. Statistical analysis: After the assessment of the data, the variables between two groups will be compared by Mann Whitney U test, Student T test, Fisher Exact Test, Chi-Square Analysis. Regression model will be conducted in order to estimate the probability of the preterm birth. A value of p \< 0.05 will be considered statistically significant.

Interventions

DIAGNOSTIC_TESTSerum sample analysis

Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels

Sponsors

Ismail Biyik
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

* Singleton pregnancy * Gestational age is between 24-37 weeks * Cervical dilatation less than 3 cm and cervical effacement less than 80% * Uterine contraction ≥3 times at 30 minutes * Intact amniotic membrane

Exclusion criteria

* Multiple pregnancy * Preterm premature rupture of membranes * Abnormal placentation (such as placenta previa) * Uterine anomaly * Maternal heart disease * Inflammatory or infectious disease * Preeclampsia * Fetal growth restriction * Congenital fetal anomaly * Polyhydramnios * Acute chorioamnionitis * Medically induced preterm delivery

Design outcomes

Primary

MeasureTime frameDescription
Gestational age at birthDecember 2019 - January 2021Preterm: \<37 gestational week Term: ≥37 gestational week

Secondary

MeasureTime frameDescription
APGAR scoreDecember 2019 - January 2021Apgar stands for Appearance, Pulse, Grimace, Activity, and Respiration. of newborn at 1 and 5 minutes after delivery.
Hospital admission and delivery intervalDecember 2019 - January 2021Delivery time will be divided into groups within; 48 hours, 7 days, 14 days, * 35 weeks and * 37 weeks after hospital admission.
Mode of deliveryDecember 2019 - January 2021Vaginal delivery Cesarean delivery

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026